Immunic

UNITY Biotechnology appoints Federico Grossi, M.D., Ph.D., as chief medical officer, leveraging his expertise in clinical development and regulatory strategy. Grossi's leadership is expected to advance UNITY's therapeutic portfolio, focusing on age-related diseases, as the company approaches critical clinical trial milestones.

Immunic, Inc. (IMUX) announced Q4 2024 presentations available on-demand, participation in December's Piper Sandler Healthcare Conference, publication of IMU-856 trial data in The Lancet, a Q3 loss of $24.4M, and positive interim analysis of Phase 3 ENSURE program for vidofludimus calcium in MS treatment.

In 2024, significant advances in multiple sclerosis (MS) included the first approved biosimilar, revised McDonald Diagnostic Criteria, promising results from the ENHANCE and DAYBREAK trials, FDA approval of the SelfJect injector, and findings on foralumab and tolebrutinib. The DAAE score was developed for risk assessment, while simvastatin failed in the MS-STAT2 trial. Physician burnout in MS care was highlighted.

GlobalData evaluates drug development using phase transition and approval likelihood scores. Vidofludimus calcium, targeting DHODH and Nurr1, is in development for multiple sclerosis and COVID-19. Immunic Therapeutics, focusing on chronic inflammatory and autoimmune diseases, develops vidofludimus calcium and other treatments.

Immunic, Inc. (Nasdaq: IMUX) announced participation in investor conferences, publication of Phase 1/1b clinical trial data for IMU-856 in The Lancet Gastroenterology & Hepatology, a Q3 loss of $24.4M, and positive interim analysis of Phase 3 ENSURE program for vidofludimus calcium in relapsing multiple sclerosis. Also, first patient enrolled in Phase 2 trial for post COVID syndrome treatment.

DelveInsight's 'Crohn's Disease Pipeline Insight, 2024' report details 70+ companies developing 80+ therapies, including AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, and Bristol-Myers Squibb. Key therapies like MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, and Brazikumab are expected to impact the market. The report covers clinical trials, regulatory approvals, market dynamics, and therapeutic assessments by route of administration and molecule type.

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report highlights 75+ companies developing 80+ therapies, including promising candidates like GA Depot, Remibrutinib, and IMU 838. Key events include Immunic's positive Phase 3 ENSURE trial interim analysis, Roche's FDA approval for Ocrevus injectable, and Sanofi's mixed results for tolebrutinib in Phase III trials. The report covers global pipeline stages, product types, molecule types, mechanisms of action, and routes of administration.

Immunic, Inc. announced the publication of phase 1/1b clinical trial data of IMU-856, a SIRT6 modulator, in The Lancet Gastroenterology & Hepatology, showing potential to treat celiac disease by restoring intestinal barrier function and improving gut health.

Immunic, Inc. reports Q3 2024 financial results and updates on its Phase 3 ENSURE program for vidofludimus calcium in relapsing multiple sclerosis, with an unblinded IDMC confirming trials should continue as planned. The company also provides updates on its Phase 2 CALLIPER trial in progressive multiple sclerosis, expecting top-line data in April 2025. Additionally, Immunic discusses its IMU-856 program for celiac disease and other clinical milestones, with a webcast scheduled for November 7, 2024.